ADAR1 Capital Management, the largest stockholder of Keros Therapeutics with approximately 13.3% of the company's outstanding shares, has released an investor presentation recommending that votes be withheld for the re-election of Dr. Mary Ann Gray and Dr. Alpna Seth to the Keros Board of Directors. This recommendation comes ahead of Keros Therapeutics' Annual Meeting of Stockholders, scheduled for June 4, 2025. ADAR1's decision and the rationale behind it can be found in their presentation, which has been made publicly accessible.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keros Therapeutics Inc published the original content used to generate this news brief via PR Newswire (Ref. ID: NY85500) on May 12, 2025, and is solely responsible for the information contained therein.